Compare Rush Street Interactive Inc (RSI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rush Street Interactive Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Rush Street Interactive Inc trades at $26.65 (market cap $3.12B), while Vertex Pharmaceuticals Incorporated trades at $521.58 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 43× Rush Street Interactive Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Rush Street Interactive Inc nearer its low. Which is the better fit depends on your goals.
| RSI | VRTX | |
|---|---|---|
Market Cap | $3.12B | $134.06B |
Sector | Technology | Health |
52-Week High | $34.52 | $557.96 |
52-Week Low | $15.89 | $376.62 |
Enterprise Value | $2.79B | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rush Street Interactive (RSI) trades at $27.02, up 1.27% today, with a bullish technical signal from moving averages and strong institutional interest. Recent Q2 2026 results showed record revenue of $393.8 million and net income of $29.3 million, beating EPS expectations. The company raised full-year 2026 guidance, reflecting robust growth in online casino and sports betting markets. Analyst consensus is strongly bullish with a $34.75 price target, indicating 29% upside potential from current levels.
The outlook for RSI is positive, driven by accelerating revenue growth and expanding market share, but risks include intense competition and regulatory scrutiny in the gambling sector. High valuation multiples like a P/E of 87.16 suggest elevated expectations, requiring continued execution. Institutional buying, such as BlackRock's $448 million investment in Q2 2026, supports confidence, though investors should monitor margin pressures from rising marketing costs.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
